Lobbying disclosures · Lobbying report
BIIB: second_quarter 2026 lobbying report
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. Intellectual property protections and enforcement. Biopharmaceutical patent policy. Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathwa
Follow BIIB- Became public
- Jul 20, 2026, 5:22 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 2:18 PM EST
Why this is connected
Exact legal-name match: BIOGEN INC. (https://www.sec.gov/Archives/edgar/data/875045/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/270f36db-1764-4e2a-958d-bbaf76169343/","filing_uuid":"270f36db-1764-4e2a-958d-bbaf76169343","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/270f36db-1764-4e2a-958d-bbaf76169343/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"William Minor, Partner","dt_posted":"2026-07-20T17:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 8th Street, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":76855,"url":"https://lda.gov/api/v1/registrants/76855/","house_registrant_id":32113,"name":"DLA PIPER LLP (US)","description":"Law firm.","address_1":"500 8th Street, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MINOR","contact_telephone":"+1 202-799-4312","dt_updated":"2026-07-30T08:35:35.415773-04:00"},"client":{"id":67421,"url":"https://lda.gov/api/v1/clients/67421/","client_id":67421,"name":"BIOGEN, INC.","general_description":"Biotechnology company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-06-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property protections and enforcement. Biopharmaceutical patent policy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to tax reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade-related public policy around tariffs and intellectual property.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in BIIB
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 7, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
$1K–$15K · Traded Sep 24, 2026 · disclosed Oct 7, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 1, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
$1K–$15K · Traded Aug 18, 2026 · disclosed Sep 1, 2026
Got $5K from the company’s PAC - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jul 7, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Jun 2, 2026 · disclosed Jul 7, 2026
- Jul 2, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Jun 5, 2026 · disclosed Jul 2, 2026
- Jun 8, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
$1K–$15K · Traded May 12, 2026 · disclosed Jun 8, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.